title: Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
abstract: OBJECTIVE
  To explore the potential of deep HIV-1 sequencing for adding clinically relevant information relative to viral population sequencing in heavily pre-treated HIV-1-infected subjects.
  
  
  METHODS
  In a proof-of-concept study, deep sequencing was compared to population sequencing in HIV-1-infected individuals with previous triple-class virological failure who also developed virologic failure to deep salvage therapy including, at least, darunavir, tipranavir, etravirine or raltegravir. Viral susceptibility was inferred before salvage therapy initiation and at virological failure using deep and population sequencing genotypes interpreted with the HIVdb, Rega and ANRS algorithms. The threshold level for mutant detection with deep sequencing was 1%.
  
  
  RESULTS
  7 subjects with previous exposure to a median of 15 antiretrovirals during a median of 13 years were included. Deep salvage therapy included darunavir, tipranavir, etravirine or raltegravir in 4, 2, 2 and 5 subjects, respectively. Self-reported treatment adherence was adequate in 4 and partial in 2; one individual underwent treatment interruption during follow-up. Deep sequencing detected all mutations found by population sequencing and identified additional resistance mutations in all but one individual, predominantly after virological failure to deep salvage therapy. Additional genotypic information led to consistent decreases in predicted susceptibility to etravirine, efavirenz, nucleoside reverse transcriptase inhibitors and indinavir in 2, 1, 2 and 1 subject, respectively. Deep sequencing data did not consistently modify the susceptibility predictions achieved with population sequencing for darunavir, tipranavir or raltegravir.
  
  
  CONCLUSIONS
  In this subset of heavily pre-treated individuals, deep sequencing improved the assessment of genotypic resistance to etravirine, but did not consistently provide additional information on darunavir, tipranavir or raltegravir susceptibility. These data may inform the design of future studies addressing the clinical value of minority drug-resistant variants in treatment-experienced subjects.
authors: Institut de Recerca de la SIDA irsiCaixa-HIVACAT, Badalona, Spain. fcodoner@gmail.com
authors: Francisco M
authors: FM
authors: Codoñer
authors: Christian
authors: C
authors: Pou
authors: Alexander
authors: A
authors: Thielen
authors: Federico
authors: F
authors: García
authors: Rafael
authors: R
authors: Delgado
authors: David
authors: D
authors: Dalmau
authors: Miguel
authors: M
authors: Álvarez-Tejado
authors: Lidia
authors: L
authors: Ruiz
authors: Bonaventura
authors: B
authors: Clotet
authors: Roger
authors: R
authors: Paredes
references: PLoS One. 2010 Jun 03;5(6):e10952
references: 20532178
references: J Clin Virol. 2011 Feb;50(2):156-61
references: 21056001
references: J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15
references: 19734799
references: Antimicrob Agents Chemother. 2006 Mar;50(3):1092-5
references: 16495277
references: J Infect Dis. 2005 Aug 1;192(3):456-65
references: 15995959
references: Arch Intern Med. 2010 Mar 8;170(5):410-9
references: 20212176
references: Clin Infect Dis. 2010 Feb 15;50(4):566-73
references: 20085464
references: PLoS Med. 2008 Jul 29;5(7):e158
references: 18666824
references: AIDS. 2011 Jan 28;25(3):325-33
references: 21157296
references: J Infect Dis. 2010 Mar;201(5):662-71
references: 20102271
references: Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43
references: 18625773
references: AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88
references: 18327986
references: PLoS One. 2009 Jun 29;4(6):e6079
references: 19562031
references: AIDS. 2008 Jul 31;22(12):1417-23
references: 18614864
references: J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73
references: 19779307
references: Nature. 2005 Sep 15;437(7057):376-80
references: 16056220
references: J Infect Dis. 2009 Mar 1;199(5):693-701
references: 19210162
references: J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):540-50
references: 17245230
references: J Clin Virol. 2009 May;45(1):34-8
references: 19375978
references: AIDS Res Hum Retroviruses. 2011 Feb;27(2):201-9
references: 20929395
references: Antimicrob Agents Chemother. 2009 Apr;53(4):1670-2
references: 19171798
references: Clin Infect Dis. 2009 Jan 15;48(2):239-47
references: 19086910
references: Antivir Ther. 2006;11(4):421-9
references: 16856615